Key result
mIL-13Rα1-mIL-4Rα-hFc fusion protein efficiently suppresses IL-4 and IL-13 signaling by inhibiting cellular CCL11 release.
The generated mIL-13Rα1-mIL-4Rα-hFc fusion protein efficiently traps both IL-4 and IL-13, suggesting potential as a therapeutic agent for type 2 inflammatory diseases.
Should not yet alter management of type 2 inflammatory diseases; extends preclinical rationale for dual IL-4/IL-13 blockade via fusion proteins.
mIL-13Rα1-mIL-4Rα-hFc protein efficiently suppressed signaling of both IL-4 and IL-13. Accordingly, the drug to efficiently trap both cytokines may be promising as alternative medicine.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2026) studied Type 2 inflammation and allergic diseases. mIL-13Rα1-mIL-4Rα-hFc protein vs. mIL-4Rα-hFc protein and hFc alone was evaluated on CCL11 release from Kera-308 cells stimulated with IL-4 or IL-13. The mIL-13Rα1-mIL-4Rα-hFc fusion protein efficiently suppressed signaling of both IL-4 and IL-13 by inhibiting CCL11 release from stimulated Kera-308 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: